Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where E. J. Kuipers is active.

Publication


Featured researches published by E. J. Kuipers.


Endoscopy | 2012

Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED)

Mário Dinis-Ribeiro; Miguel Areia; A. C. de Vries; Ricardo Marcos-Pinto; M. Monteiro-Soares; A. O’Connor; Cidália Dionísio Pereira; Pedro Pimentel-Nunes; Rui Correia; Arzu Ensari; Jean-Marc Dumonceau; José Carlos Machado; Guilherme Macedo; Peter Malfertheiner; Tamara Matysiak-Budnik; Francis Mégraud; K. Miki; Colm O’Morain; Richard M. Peek; Thierry Ponchon; Ari Ristimäki; B. Rembacken; Fátima Carneiro; E. J. Kuipers

Atrophic gastritis, intestinal metaplasia, and epithelial dysplasia of the stomach are common and are associated with an increased risk for gastric cancer. In the absence of guidelines, there is wide disparity in the management of patients with these premalignant conditions. The European Society of Gastrointestinal Endoscopy (ESGE), the European Helicobacter Study Group (EHSG), the European Society of Pathology (ESP) and the Sociedade Portuguesa de Endoscopia Digestiva (SPED) have therefore combined efforts to develop evidence-based guidelines on the management of patients with precancerous conditions and lesions of the stomach (termed MAPS). A multidisciplinary group of 63 experts from 24 countries developed these recommendations by means of repeat online voting and a meeting in June 2011 in Porto, Portugal. The recommendations emphasize the increased cancer risk in patients with gastric atrophy and metaplasia, and the need for adequate staging in the case of high grade dysplasia, and they focus on treatment and surveillance indications and methods.


Gut | 2010

Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy

Lieke Hol; M E van Leerdam; M. van Ballegooijen; A J van Vuuren; H. van Dekken; Jacqueline C. Reijerink; A C M van der Togt; J. D. F. Habbema; E. J. Kuipers

Background: Screening for colorectal cancer (CRC) is widely accepted, but there is no consensus on the preferred strategy. We conducted a randomised trial comparing participation and detection rates (DR) per screenee of guaiac-based faecal occult blood test (gFOBT), immunochemical FOBT (FIT), and flexible sigmoidoscopy (FS) for CRC screening. Methods: A representative sample of the Dutch population (n = 15 011), aged 50–74 years, was 1:1:1 randomised prior to invitation to one of the three screening strategies. Colonoscopy was indicated for screenees with a positive gFOBT or FIT, and for those in whom FS revealed a polyp with a diameter ⩾10 mm; adenoma with ⩾25% villous component or high grade dysplasia; serrated adenoma; ⩾3 adenomas; ⩾20 hyperplastic polyps; or CRC. Results: The participation rate was 49.5% (95% confidence interval (CI) 48.1 to 50.9%) for gFOBT, 61.5% (CI, 60.1 to 62.9%) for FIT and 32.4% (CI, 31.1 to 33.7%) for FS screening. gFOBT was positive in 2.8%, FIT in 4.8% and FS in 10.2%. The DR of advanced neoplasia was significantly higher in the FIT (2.4%; OR, 2.0; CI, 1.3 to 3.1) and the FS arm (8.0%; OR, 7.0; CI, 4.6 to 10.7) than the gFOBT arm (1.1%). FS demonstrated a higher diagnostic yield of advanced neoplasia per 100 invitees (2.4; CI, 2.0 to 2.8) than gFOBT (0.6; CI, 0.4 to 0.8) or FIT (1.5; CI, 1.2 to 1.9) screening. Conclusion: This randomised population-based CRC-screening trial demonstrated superior participation and detection rates for FIT compared to gFOBT screening. FIT screening should therefore be strongly preferred over gFOBT screening. FS screening demonstrated a higher diagnostic yield per 100 invitees than both FOBTs.


British Journal of Cancer | 2009

Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels

Lieke Hol; Janneke Wilschut; M. van Ballegooijen; A J van Vuuren; H van der Valk; Jacqueline C. Reijerink; A C M van der Togt; E. J. Kuipers; J. D. F. Habbema; M E van Leerdam

Immunochemical faecal occult blood testing (FIT) provides quantitative test results, which allows optimisation of the cut-off value for follow-up colonoscopy. We conducted a randomised population-based trial to determine test characteristics of FIT (OC-Sensor micro, Eiken, Japan) screening at different cut-off levels and compare these with guaiac-based faecal occult blood test (gFOBT) screening in an average risk population. A representative sample of the Dutch population (n=10 011), aged 50–74 years, was 1 : 1 randomised before invitation to gFOBT and FIT screening. Colonoscopy was offered to screenees with a positive gFOBT or FIT (cut-off 50 ng haemoglobin/ml). When varying the cut-off level between 50 and 200 ng ml−1, the positivity rate of FIT ranged between 8.1% (95% CI: 7.2–9.1%) and 3.5% (95% CI: 2.9–4.2%), the detection rate of advanced neoplasia ranged between 3.2% (95% CI: 2.6–3.9%) and 2.1% (95% CI: 1.6–2.6%), and the specificity ranged between 95.5% (95% CI: 94.5–96.3%) and 98.8% (95% CI: 98.4–99.0%). At a cut-off value of 75 ng ml−1, the detection rate was two times higher than with gFOBT screening (gFOBT: 1.2%; FIT: 2.5%; P<0.001), whereas the number needed to scope (NNscope) to find one screenee with advanced neoplasia was similar (2.2 vs 1.9; P=0.69). Immunochemical faecal occult blood testing is considerably more effective than gFOBT screening within the range of tested cut-off values. From our experience, a cut-off value of 75 ng ml−1 provided an adequate positivity rate and an acceptable trade-off between detection rate and NNscope.


Gut | 2004

Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial

E. J. Kuipers; G F Nelis; Elly C. Klinkenberg-Knol; P Snel; D Goldfain; J J Kolkman; H P M Festen; P Zeitoun; N Havu; M Lamm; A Walan

Background:Helicobacter pylori gastritis may progress to glandular atrophy and intestinal metaplasia, conditions that predispose to gastric cancer. Profound suppression of gastric acid is associated with increased severity of H pylori gastritis. This prospective randomised study aimed to investigate whether H pylori eradication can influence gastritis and its sequelae during long term omeprazole therapy for gastro-oesophageal reflux disease (GORD). Methods: A total of 231 H pylori positive GORD patients who had been treated for ⩾12 months with omeprazole maintenance therapy (OM) were randomised to either continuation of OM (OM only; n = 120) or OM plus a one week course of omeprazole, amoxycillin, and clarithromycin (OM triple; n = 111). Endoscopy with standardised biopsy sampling as well as symptom evaluation were performed at baseline and after one and two years. Gastritis was assessed according to the Sydney classification system for activity, inflammation, atrophy, intestinal metaplasia, and H pylori density. Results: Corpus gastritis activity at entry was moderate or severe in 50% and 55% of the OM only and OM triple groups, respectively. In the OM triple group, H pylori was eradicated in 90 (88%) patients, and activity and inflammation decreased substantially in both the antrum and corpus (p<0.001, baseline v two years). Atrophic gastritis also improved in the corpus (p<0.001) but not in the antrum. In the 83 OM only patients with continuing infection, there was no change in antral and corpus gastritis activity or atrophy, but inflammation increased (p<0.01). H pylori eradication did not alter the dose of omeprazole required, or reflux symptoms. Conclusions: Most H pylori positive GORD patients have a corpus predominant pangastritis during omeprazole maintenance therapy. Eradication of H pylori eliminates gastric mucosal inflammation and induces regression of corpus glandular atrophy. H pylori eradication did not worsen reflux disease or lead to a need for increased omeprazole maintenance dose. We therefore recommend eradication of H pylori in GORD patients receiving long term acid suppression.


The American Journal of Gastroenterology | 2009

The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer

Jan-Werner Poley; Irma Kluijt; Dirk J. Gouma; Femme Harinck; Anja Wagner; Cora M. Aalfs; C.H.J. van Eijck; Annemieke Cats; E. J. Kuipers; Yung Nio; Paul Fockens; Marco J. Bruno

OBJECTIVES:Approximately 10–15% of all pancreatic cancers (PCs) may be hereditary in origin. We investigated the use of endoscopic ultrasonography (EUS) for the screening of individuals at high risk for developing PC. In this paper the results of first-time screening with EUS are presented.METHODS:Those eligible for screening in this study were first-degree family members of affected individuals from familial pancreatic cancer (FPC) families, mutation carriers of PC-prone hereditary syndromes, individuals with Peutz–Jeghers syndrome, and mutation carriers of other PC-prone hereditary syndromes with clustering (≥2 cases per family) of PC. All individuals were asymptomatic and had not undergone EUS before.RESULTS:Forty-four individuals (M/F 18/26), aged 32–75 years underwent screening with EUS. Thirteen were from families with familial atypical multiple-mole melanoma (FAMMM), 21 with FPC, 3 individuals were diagnosed with hereditary pancreatitis, 2 were Peutz–Jeghers patients, 3 were BRCA1 and 2 were BRCA2 mutation carriers with familial clustering of PC, and 1 individual had a p53 mutation. Three (6.8%) patients had an asymptomatic mass lesion (12, 27, and 50 mm) in the body (n=2) or tail of the pancreas. All lesions were completely resected. Pathology showed moderately differentiated adenocarcinomas with N1 disease in the two patients with the largest lesions. EUS showed branch-type intraductal papillary mucinous neoplasia (IPMN) in seven individuals.CONCLUSIONS:Screening of individuals at a high risk for PC with EUS is feasible and safe. The incidence of clinically relevant findings at first screening is high with asymptomatic cancer in 7% and premalignant IPMN-like lesions in 16% in our series. Whether screening improves survival remains to be determined, as does the optimal screening interval with EUS.


Histopathology | 2007

Grading of dysplasia in Barrett's oesophagus: Substantial interobserver variation between general and gastrointestinal pathologists

M Kerkhof; H. van Dekken; Ewout W. Steyerberg; Gerrit A. Meijer; Andries H. Mulder; A de Bruine; A. Driessen; F. J. W. Ten Kate; Johannes G. Kusters; E. J. Kuipers; P. D. Siersema

Aims:  To determine interobserver variation in grading of dysplasia in Barretts oesophagus (BO) between non‐expert general pathologists and expert gastrointestinal pathologists on the one hand and between expert pathologists on the other hand.


Alimentary Pharmacology & Therapeutics | 2008

Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease

R. L. West; Z. Zelinkova; G.J. Wolbink; E. J. Kuipers; Pieter Stokkers; C.J. van der Woude

Background  Adalimumab is an effective treatment in patients with Crohn’s disease; as it is a humanized anti‐tumour necrosis factor monoclonal antibody, immunogenicity is thought not to be of any significance.


Alimentary Pharmacology & Therapeutics | 2004

Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: A double-blind placebo-controlled study

R. L. West; C.J. van der Woude; Bettina E. Hansen; R. J. F. Felt-Bersma; A. J. P. van Tilburg; J. A. G. Drapers; E. J. Kuipers

Background : Ciprofloxacin is effective in perianal Crohns disease but after treatment discontinuation symptoms reoccur. Infliximab is effective but requires maintenance therapy.


Gut | 2004

5-Aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett’s oesophagus: a randomised trial

Mariska Hage; P. D. Siersema; H. van Dekken; Ewout W. Steyerberg; Jelle Haringsma; W van de Vrie; T E Grool; R L P van Veen; H.J.C.M. Sterenborg; E. J. Kuipers

Background: Photochemical and thermal methods are used for ablating Barrett’s oesophagus (BO). The aim of this study was to compare 5-aminolevulinic acid induced photodynamic therapy (ALA-PDT) with argon plasma coagulation (APC) with respect to complete reversal of BO. Methods: Patients with BO (32 no dysplasia and eight low grade dysplasia) were randomised to one of three treatments: (a) ALA-PDT as a single dose of 100 J/cm2 at four hours (PDT100; n = 13); (b) ALA-PDT as a fractionated dose of 20 and 100 J/cm2 at one and four hours, respectively (PDT20+100; n = 13); or (c) APC at a power setting of 65 W in two sessions (APC; n = 14). If complete elimination of BO was not achieved by the designated treatment, the remaining BO was treated by a maximum of two sessions of APC. Results: Mean endoscopic reduction of BO at six weeks was 51% (range 20–100%) in the PDT100 group, 86% (range 0–100%) in the PDT20+100 group, and 93% (range 40–100%) in the APC group (PDT100 v PDT20+100, p<0.005; PDT100 v APC, p<0.005; and PDT20+100 v APC, NS) with histologically complete ablation in 1/13 (8%) patients in the PDT100 group, 4/12 (33%) in the PDT20+100 group, and 5/14 (36%) in the APC group (NS). Remaining BO was additionally treated with APC in 23/40 (58%) patients. Histological examination at 12 months revealed complete ablation in 9/11 (82%) patients in the PDT100 group, in 9/10 (90%) patients in the PDT20+100 group, and in 8/12 (67%) patients in the APC group (NS). At 12 months, no dysplasia was detected. Side effects (that is, pain (p<0.01), and nausea and vomiting (p<0.05)) and elevated liver transaminases (p<0.01) were more common after PDT than APC therapy. One patient died three days after treatment with PDT, presumably from cardiac arrhythmia. Conclusion: APC alone or ALA-PDT in combination with APC can lead to complete reversal of Barrett’s epithelium in at least two thirds of patients when administered in multiple treatment sessions. As the goal of treatment should be complete reversal of Barrett’s epithelium, we do not recommend these techniques for the prophylactic ablation of BO.


Alimentary Pharmacology & Therapeutics | 2011

High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy

Z. Zelinkova; C. de Haar; L. de Ridder; Marie Pierik; E. J. Kuipers; Maikel P. Peppelenbosch; C.J. van der Woude

Aliment Pharmacol Ther 2011; 33: 1053–1058

Collaboration


Dive into the E. J. Kuipers's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ewout W. Steyerberg

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

M E van Leerdam

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

C.J. van der Woude

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

P. D. Siersema

Erasmus University Medical Center

View shared research outputs
Top Co-Authors

Avatar

H. van Dekken

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Jelle Haringsma

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Peter Mensink

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Judith E. Baars

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

M. van Ballegooijen

Erasmus University Rotterdam

View shared research outputs
Researchain Logo
Decentralizing Knowledge